Takhzyro Європейський Союз - норвезька - EMA (European Medicines Agency)

takhzyro

takeda pharmaceuticals international ag ireland branch - lanadelumab - angioødemer, arvelig - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.